Hims & Hers Stock (HIMS) Plunge: A Hidden Buying Opportunity?

HIMS just took a nosedive—but smart money might be circling.

Why the crash could be your gain

The telehealth darling got hammered, but here’s the twist: fundamentals haven’t changed. Same growth trajectory, same addressable market—just a cheaper entry point. Classic Wall Street overreaction.

When the herd panics, winners load up

Remember: Amazon crashed 90% during the dot-com bust. Today’s ‘disaster’ often becomes tomorrow’s ‘why didn’t I buy?’ moment. (Cue the usual hedge fund crocodile tears.)

Bottom line: Blood in the streets? Maybe. But sharks smell opportunity.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Hims Stock in the Spotlight

In the past five days, Hims & Hers has ranked among the most purchased stocks on Interactive Brokers, surpassing even big tech giants. According to Interactive Brokers’ chief strategist Steve Sosnick, HIMS stock drew in “opportunistic buyers,” despite a sharp drop.

Sosnick cautioned that it may take time to determine whether investors are wisely buying the dip or prematurely catching a falling knife. Meanwhile, options activity on the platform has shown a clear bullish tilt, suggesting some traders remain confident in a rebound.

Year-to-date, HIMS stock has gained over 75% in trading.

Short-Term Pain, Long-Term Potential Intact

Following the termination, five-star-rated analyst Maria Ripps of Canaccord Genuity maintained her Buy rating on HIMS stock, projecting a potential upside of 58%. Ripps remains confident in Hims & Hers’ long-term growth, noting that its FY2025 guidance is still within reach despite the Novo breakup, as it wasn’t dependent on the deal. She also points to strategic drivers like new product launches, stronger marketing, and potential global expansion to fuel growth in late 2025 and beyond.

Furthermore, despite recent volatility, the long-term outlook for the GLP-1 market remains strong, with some analysts projecting it could surpass $150 billion by 2035. While losing the Novo partnership is a setback, Hims still has the potential to tap into this growth through compounding or new strategic alliances.

Is HIMS a Good Stock to Buy Right Now?

Overall, Wall Street analysts have a Hold consensus rating on HIMS stock based on one Buy, eight Holds, and two Sells assigned in the last three months. The average HIMS stock price target of $39.80 implies a downside of 7% from the current trading level.